MKM Upgrades Merck to a “Buy” (MRK)
MKM reported on Tuesday that they have upgraded healthcare company, Merck & Co., Inc.(MRK) to a “Buy”.
The firm reported that they have upgraded MRK from “Neutral” to a “Buy,” and have given the company a price target of $51. This price target suggests a 15% increase over the stock’s current price of $43.38.
Merck & Co. shares were mostly flat during premarket trading Tuesday. The stock is up 14.96% YTD.
The Bottom Line
Shares of Merck (MRK) have a 3.81% dividend yield, based on last night’s closing stock price of $43.34. The stock has technical support in the $41-$42 price area. If the shares can firm up, we see overhead resistance around the $46-$48 price levels.
Merck & Co., Inc.(MRK) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability